Trial Profile
A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary) ; Venetoclax (Primary) ; Corticosteroids; Dexamethasone; Dexamethasone; Rituximab
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 19 Jul 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 19 Jul 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.
- 02 Dec 2022 Planned End Date changed from 31 Jan 2023 to 31 Aug 2023.